The global carrier screening market size was valued at approximately USD 2.46 billion in 2023 and is projected to reach USD 6.5 billion by 2032, growing at a compound annual growth rate (CAGR) of 13.8% from 2024 to 2032. Carrier screening, a genetic test used to identify if an individual carries a gene for specific genetic disorders, is pivotal in determining the risk of having a child with a genetic disorder when performed before or during pregnancy. The testing process involves analysing a sample of blood, saliva, or tissue from the inside of the cheek. Results indicate either a negative status (non-carrier) or a positive status (carrier), typically starting with the partner most likely to be a carrier.
The market growth is driven by increasing awareness about genetic disorders and the benefits of early detection through carrier screening. This growing awareness, coupled with an emphasis on family planning and preventative healthcare, is fuelling demand. Carrier screening empowers individuals and couples to understand their genetic predisposition to hereditary conditions, thereby facilitating informed reproductive decisions. Also, Technological advancements in genetic testing, including next-generation sequencing (NGS) and expanded carrier screening panels, have significantly enhanced the accuracy, comprehensiveness, and cost-effectiveness of these tests. These advancements enable the detection of a broader range of genetic mutations and improve accessibility, further encouraging the uptake of carrier screening. Moreover, supportive government policies and initiatives play a crucial role in promoting the adoption of genetic screening. Many governments are integrating genetic screening into public health programs, which not only boosts market penetration but also creates a favorable regulatory environment for market growth.
Emerging markets present significant growth opportunities due to expanding healthcare infrastructure and increasing healthcare expenditure. As awareness and affordability of genetic testing rise in these regions, the demand for carrier screening services is expected to grow, offering lucrative opportunities for market players. Additionally, the integration of carrier screening with personalized medicine approaches offers substantial growth potential by providing valuable genetic information that supports individualized healthcare strategies.
However, the market faces challenges related to ethical and privacy concerns. Issues surrounding data security, potential discrimination, and the ethical implications of genetic information can deter individuals from undergoing testing and create regulatory hurdles, potentially hindering market growth.
North America was the dominant region in the carrier screening market and is expected to maintain its dominance throughout the forecast period. This is attributed to the high prevalence rate of genetic diseases like cystic fibrosis, an increase in the number of market players, and a surge in the availability of tests in the region. Conversely, Asia-Pacific is expected to witness the highest CAGR during the analysis period, driven by the high population in countries such as India and China, which increases the likelihood of genetic conditions, and the increasing number of strategies and trends adopted by market players. The enhanced infrastructure of healthcare facilities, well-designed reimbursement policies, and improving economic factors in Asia-Pacific are expected to positively impact the market growth. Additionally, increasing initiatives by non-profit organizations in the region are anticipated to further boost the market.
Major market players included in this report are:
Natera Inc.
Eurofins Scientific
InVitae Corporation
Illumina Inc.
Myriad Genetics, Inc.
Thermo Fisher Scientific Inc.
Fulgent Genetics Inc.
Quest Diagnostics Inc.
Diasorin S.p.A.
Opko Health Inc.
The detailed segments and sub-segments of the market are explained below:
By Type:
Expanded Carrier Screening
Targeted Disease Carrier Screening
By Technology:
DNA Sequencing
Polymerase Chain Reaction
Microarrays
Others
By End User:
Hospitals and Clinics
Reference Laboratories
Physician Offices
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Middle East & Africa
Saudi Arabia
South Africa
RoMEA
Years considered for the study are as follows:
Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032
Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market
